Clinical value of quantitative 99Tc m-HYNIC-PSMA SPECT/CT in the diagnosis of prostate cancer
10.3760/cma.j.cn321828-20210407-00099
- VernacularTitle:定量 99Tc m-HYNIC-PSMA SPECT/CT诊断前列腺癌的价值
- Author:
Jingqi SHI
1
;
Xinyu WU
;
Bo LI
;
Xiaobo WANG
;
Lili DUAN
;
Xiemei RUAN
;
Junling XU
;
Degang DING
;
Yongju GAO
Author Information
1. 郑州大学人民医院、河南省人民医院核医学科；河南省核医学新型分子探针与临床转化医学重点实验室，郑州 450003
- Keywords:
Prostatic neoplasms;
Prostate-specific membrane antigen;
Technetium;
Neoplasm metastasis;
Tomography, emission-computed, single-photon;
Tomography, X-ray c
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(3):149-153
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the diagnostic value of quantitative 99Tc m-hydrazinonicotinamide(HYNIC)-prostate specific membrane antigen (PSMA) SPECT/CT in patients with prostate cancer. Methods:From November 2018 to March 2021, the data of 56 patients ((69.8±8.0) years) with clinically suspected prostate cancer, who had elevated radioactive uptake in prostate on 99Tc m-HYNIC-PSMA SPECT/CT images in Henan Provincial People′s Hospital, were retrospectively analyzed. According to the pathological results, patients were divided into prostate cancer group ( n=45) and non-prostate cancer group ( n=11). The xSPECT-QUANT software was used to quantitatively analyze the high uptake area of the prostate, and SUV max was measured. The independent-sample t test, Mann-Whitney U test, ROC curve and Spearman correlation analysis were used for data analysis. Results:The prostate cancer group had higher SUV max than non-prostate cancer group (10.79±5.96 vs 3.60±1.27; t=7.43, P<0.001). When SUV max≥6.46, the AUC of prostate cancer was 0.887, with the diagnostic sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 73.3%(33/45), 11/11, 100%(33/33), 47.8%(11/23), 78.6%(44/56), respectively. The SUV max of prostate cancer group was positively correlated with Gleason score ( rs=0.632, P<0.001). The SUV max of 29 patients with Gleason score≥8 was higher than that of 16 patients with Gleason score≤7 ( z=-3.89, P<0.001). There was no statistical difference in PSA level between patients with Gleason score≤ 7 and patients with non-prostate cancer ( z=-1.63, P=0.110), but the SUV max was significantly different ( z=-2.22, P=0.026). The SUV max of 23 patients with metastases was higher than that of 22 patients without metastasis (12.99±5.85 vs 8.50±5.28; t=2.69, P=0.010). ROC analysis showed that the AUC was 0.709; with SUV max≥13.02 as the threshold, the sensitivity for diagnosing prostate cancer metastases was 56.5%(13/23), the specificity was 86.4%(19/22), and the accuracy was 71.1%(32/45). Conclusions:The 99Tc m-HYNIC-PSMA SPECT/CT quantitative analysis is feasible in patients with prostate cancer. SUV max of 99Tc m-HYNIC-PSMA can be used in the diagnosis of prostate cancer, assessment of the malignancy and prediction of metastasis.
